Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia

Phase 3

Completed

• Conditions: Hypertension; Dyslipidemia

• Registration Number: NCT00330785
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Study Completion: 2005-09
• Study First Submitted: 2006-02-28
• Study First Submitted QC: 2006-05-26
• Study First Posted: 2006-05-29
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-26
• Last Update Posted: 2021-01-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1250

Inclusion Criteria

• Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion Criteria

• High liver enzymes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
LDL-C targets as defined by their governing guidelines.
To evaluate the number of patients who reach target blood pressure (BP) and

Secondary Outcome Measures

Name	Time	Method
cholesterol (HDL-C), HDL-C/LDL-C ratio, TC/HDL-C ratio. Systolic Blood Pressure
parameters: LDL-C, total cholesterol (TC), triglycerides, high-density lipoprotein
To assess changes from baseline to end of treatment for the following efficacy
(SBP) and Diastolic Blood Pressue (DBP).

Trial Locations

Locations (1)

Pfizer Investigational Site